An additional patient received anti-HER2 after three lines of therapy, responded in all areas except brain (noting that trastuzumab has poor penetration for blood-brain barrier; Table 2; ID:4, gallbladder cancer, positive for HER2 in all three assays [CNV/mRNA/IHC], PFS: 1.5 months), and passed away. This evidence concerns the gene ERBB2 and gallbladder cancer.